Franklin Resources Inc. Cuts Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Franklin Resources Inc. decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 21.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,342,500 shares of the company’s stock after selling 371,996 shares during the quarter. Franklin Resources Inc. owned approximately 1.32% of Dyne Therapeutics worth $44,719,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of DYN. Nisa Investment Advisors LLC increased its holdings in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the period. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics in the 3rd quarter valued at about $34,000. Point72 DIFC Ltd purchased a new position in shares of Dyne Therapeutics in the 3rd quarter valued at about $36,000. US Bancorp DE increased its holdings in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Dyne Therapeutics in the 3rd quarter valued at about $62,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Up 0.2 %

Dyne Therapeutics stock opened at $26.16 on Wednesday. Dyne Therapeutics, Inc. has a twelve month low of $11.66 and a twelve month high of $47.45. The stock has a 50 day moving average of $30.14 and a two-hundred day moving average of $35.19. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -7.35 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Equities analysts predict that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Wall Street Analyst Weigh In

DYN has been the topic of a number of recent analyst reports. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Royal Bank of Canada initiated coverage on Dyne Therapeutics in a report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price objective on the stock. Robert W. Baird initiated coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective on the stock. Finally, Chardan Capital reiterated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $50.42.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. This trade represents a 25.33 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 167,341 shares of company stock valued at $5,862,564. 20.77% of the stock is owned by company insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.